The University of Texas Medical Branch at GalvestonUnited States
Dr. Fnu Aakash serves as Interim Director of Hematopathology and Assistant Professor in the Department of Pathology at the University of Texas Medical Branch. His research focuses on hematopathology, oncology diagnostics, and clinical significance of neoplastic disorders. With an h-index of 55, Aakash has contributed significantly to cancer classification systems through publications in Modern Pathology and American Journal of Surgical Pathology. His recent work includes developing international consensus guidelines for myelodysplastic neoplasms and characterizing non-neoplastic changes associated with breast implants. Research collaborations span multiple institutions including MD Anderson Cancer Center, with specialization in malignant hematology and lymphoma diagnostics.
Alexa Siddon, MD, is an Assistant Professor in the Department of Laboratory Medicine at Yale School of Medicine, with secondary appointments in Pathology. She serves as Hematopathology Fellowship Director, Director of the Molecular Diagnostics Laboratory, Director of Flow Cytometry, and Associate Director of the Hematology Laboratory. She is also affiliated with the Yale Cancer Center, Clinical Flow Cytometry Laboratory, and the Hematopathology Laboratory at the Veteran Affairs Connecticut Healthcare System. Dr. Siddon's research focuses on hematopathology, particularly myeloid malignancies, acute leukemias, and post-transplant monitoring. Her work integrates molecular diagnostics, flow cytometry, and genomic analysis to improve patient diagnosis and outcomes. She has co-authored over 10 peer-reviewed articles in recent years, frequently collaborating with leading hematologists and pathologists such as Christopher Tormey, Henry Rinder, and Rory Shallis. Her publications reveal a strong trend in translational research, emphasizing the clinical implications of genetic mutations (e.g., TP53, NPM1, IDH1/2), chimerism testing post-transplant, and immunophenotypic characterization of hematologic malignancies. The research spans disciplines including oncology, molecular biology, immunology, and clinical pathology, with a clear focus on precision diagnostics and prognostic modeling. Scientific Awards: ASCP Distinguished Educator Award Paul J. Strandjord Young Investigator Award Donald H. Buchholz Research Prize Dr. Siddon is actively involved in medical education, directing fellowship programs and mentoring trainees. She has no reported grants listed in the text, but her leadership in diagnostic laboratories and active publication record suggest ongoing research funding. She is not part-time, not retired, and remains a current, active faculty member. She is affiliated with multiple research entities including the Cancer Immunology Center, Center for Biomedical Data Science, and the Yale Cancer Center, contributing to interdisciplinary teams focused on hematologic malignancies and diagnostic innovation.
Professor Faye Rogers serves as Professor of Therapeutic Radiology at Yale University School of Medicine, holding multiple leadership positions including Associate Cancer Center Director for YCC Collaborative Excellence, Vice Chair for Collaborative Excellence in Therapeutic Radiology, Associate Director of the Yale MD-PhD Program, and Director of the Yale BioMed Amgen Scholars Program. Her work bridges radiation oncology, DNA repair mechanisms, and cancer therapeutics within Yale's comprehensive cancer research ecosystem. PhD from University of Maryland at Baltimore (1998) Postdoctoral Fellow at Yale School of Medicine Dr. Rogers' research focuses on the intersection of DNA repair mechanisms and cancer therapeutics, with particular expertise in triplex DNA structures, genomic instability, and targeted cancer therapies. Her work explores how DNA damage responses can be leveraged for therapeutic benefit, especially in breast neoplasms and other malignancies. Through her leadership in the DNA Damage and Genome Integrity program, she investigates novel approaches to disrupt cancer cell survival mechanisms while sparing healthy tissue. Her research has significant implications for radiation oncology, particularly in developing more precise and effective radiation-based treatments. Analysis of Dr. Rogers' publication record reveals a consistent trajectory in DNA repair mechanisms and cancer therapeutics, with increasing focus on translational applications. Her work demonstrates expertise in triplex DNA structures, RAD51 inhibition, and synthetic lethality approaches. Recent publications show a shift toward more clinically applicable research, particularly in targeting DNA repair pathways in specific cancer subtypes like IDH1-mutant cancers and PTEN-deficient glioblastomas. Her collaborative work with Peter Glazer and others demonstrates strong interdisciplinary connections between radiation oncology, molecular biology, and drug development. Leadership in Diversity, Equity & Inclusion Award (Yale School of Medicine, 2022) Translational Science Research Prize (Yale Cancer Center, 2022) Kingsley Fellowship in Medical Research Carl Storm Underrepresented Minority Fellowship NCI Research Supplement to Promote Diversity in Health-Related Research As Associate Director of the Yale MD-PhD Program and Director of the Yale BioMed Amgen Scholars Program, Dr. Rogers plays a pivotal role in mentoring the next generation of physician-scientists and supporting underrepresented minorities in biomedical research. Her leadership in collaborative excellence initiatives demonstrates commitment to fostering interdisciplinary research teams across Yale's scientific ecosystem. Through the YCC Collaborative Excellence program, she has secured significant funding for innovative cancer research that bridges basic science and clinical applications, particularly in the areas of DNA repair targeting and radiation oncology. Dr. Rogers leads research within Yale's Therapeutic Radiology department, with strong connections to the Radiobiology program and the Yale Cancer Center. Her work is integrated with the Program in Translational Biomedicine and the Yale Combined Program in the Biological and Biomedical Sciences. Through the BioMed Amgen Scholars Program, she provides critical research opportunities for undergraduate students, particularly those from underrepresented backgrounds, fostering talent in DNA repair research and cancer therapeutics.
Howard J. Meyerson is a Professor in the Department of Pathology at Case Western Reserve University's School of Medicine. He serves as a member of the Immune Oncology Program at the Case Comprehensive Cancer Center. His primary roles include Program Director of Hematopathology and Director of Flow Cytometry at University Hospitals Cleveland Medical Center. Research focuses on hematopoietic neoplasms classification, flow cytometric analysis, and immune cell subset evaluation in disorders and therapies. Key collaborations involve high-resolution phenotypic analysis techniques and amplification staining for neoplasm evaluation. Publications emphasize hematologic malignancies, flow cytometry advancements, and immunological mechanisms in blood disorders. Notable works include studies on FLT3-ITD detection in AML, B-ALL diagnostic markers, and clonal cytopenia characterization. Education : MD degree from Case Western Reserve University Professional activities include leadership in clinical pathology training programs and diagnostic laboratory management. Active in collaborative research on immune cell dynamics and therapeutic intervention analysis. Labs/Teams: Leads flow cytometry core facilities and participates in multi-institutional studies on hematologic malignancies.
Mayo Clinic College of Medicine and ScienceUnited States
Eapen K. Jacob, M.D. is a Professor in the Department of Laboratory Medicine and Pathology at Mayo Clinic in Rochester, Minnesota. He serves as Chair of the Cell Therapy Fellowship Directors Working Group and is actively involved in multiple committees including the MW Cellular Molecular and Bispecifics Steering Committee and the DLMP Clinical Practice Committee. Dr. Jacob received his medical degree from Mayo Medical School in 1998. His extensive training includes fellowships in Transfusion Medicine (2009) and Hematopathology (2007) at Mayo Clinic, a Visiting Clinician position in Transfusion Medicine and Cell Therapy at University of Minnesota Hospital & Clinic (2008), and multiple residency programs in Anatomic and Clinical Pathology, Surgical Pathology, and Ophthalmology at Mayo Clinic. Dr. Jacob's research focuses on Transfusion Medicine, Hematopathology, and Cellular Therapy. His work spans stem cell transplantation, immunohematology, blood banking, and autoimmune hemolytic anemia. He has made significant contributions to understanding cold agglutinin disease, stem cell processing techniques, and CAR-T cell therapy. His research often bridges laboratory medicine with clinical applications, particularly in the context of bone marrow transplantation and blood disorders. Analysis of Dr. Jacob's recent publications reveals a strong focus on cellular therapy, stem cell transplantation, and transfusion medicine. His work addresses critical challenges in cell processing, cryopreservation techniques, and the immunological aspects of transplantation. There is a clear trend toward innovative approaches in CAR-T therapy and the optimization of stem cell transplantation protocols, reflecting the evolving landscape of hematologic malignancy treatment. 2025 DLMP Innovation and Leadership in Education Award Consultant Faculty Nomination 2024 DLMP Innovation and Leadership in Education Award Consultant Faculty Nomination 2020 Innovation Award DLMP Translational Research, Innovation and Test Development Office 2017 Excellence Through Teamwork Award 2005 Best Case Presentation College of American Pathologists National Meeting 2004 Co-Chief Resident 2004 Gastrointestinal Pathology Society Award for clinical research Dr. Jacob plays a significant role in medical education as Chair of the Cell Therapy Fellowship Directors Working Group and has been instrumental in developing fellowship training programs for cellular therapy laboratory directors. His leadership extends to multiple committees focused on cell therapy, transfusion medicine, and laboratory pathology. While specific grant information isn't detailed in the provided text, his extensive publication record and leadership roles suggest substantial research funding support. Dr. Jacob is actively involved with Mayo Clinic's Cellular Therapy Laboratory and Transfusion Medicine services. He collaborates with the Bone Marrow Transplant Program and works closely with the Translational Research, Innovation and Test Development Office (TRITDO). His work impacts patient care through innovations in stem cell processing, blood product management, and cellular therapy applications.
Dr. Nabil M Ahmed is a Professor at Baylor College of Medicine, specializing in Pediatrics-Hem-Onc Cell & Gene and affiliated with the Dan L Duncan Comprehensive Cancer Center. His research focuses on adoptive immunotherapy using gene-modified T cells to target brain tumors like glioblastoma and osteosarcoma, with clinical trials approved by FDA/IRB/RAC/IBC. He leads 3 active clinical trials and has pioneered studies on tumor-specific T cell efficacy, including targeting tumor stem cells and improving T cell migration to brain tumors. His work integrates cell and gene therapy with translational research, emphasizing CAR T-cell engineering and combination therapies. Professional interests include bone marrow transplantation and cell therapy for malignant solid tumors. Research highlights include demonstrating tumor niche modulation by T cells and developing delivery systems for CAR T cells to brain tumors. Key contributions span preclinical and clinical studies, including trials of HER2-specific CAR T cells in sarcoma and glioblastoma. Affiliations include Texas Children's Hospital clinics and laboratories at the Baylor College of Medicine campus. His publications address CAR T-cell design, oncolytic virus therapies, and long-term safety of immune effector therapies.
University of California, Los AngelesUnited States
Julian Antonio Martinez-Agosto is an Associate Professor at the UCLA School of Medicine with appointments in the Department of Human Genetics, Pediatrics, and Psychiatry and Biobehavioral Sciences. Board-certified in Medical Genetics, he has served on the UCLA faculty since 2007 after completing his MD/PhD at Yale University and pediatric training at Mattel Children's Hospital UCLA. His research focuses on novel growth regulatory pathways in progenitor and stem cell maintenance, particularly studying human growth disorders with cancer predisposition. Yale University: MD/PhD in Medicine/Neuroscience (2000) UCLA: Pediatric Residency and Medical Genetics Training Postdoctoral Fellow: Laboratory of Utpal Banerjee at UCLA Dr. Martinez-Agosto's research spans genetics, developmental biology, and neurogenetics with specific emphasis on overgrowth disorders, cancer predisposition syndromes, and autism spectrum disorders. His laboratory investigates molecular pathways including PTEN, mTOR, and other growth regulatory mechanisms using both human clinical studies and Drosophila models. His clinical practice focuses on genetic syndromes leading to overgrowth, vascular malformations, and cancer predisposition. His recent publications reveal strong trends in autism genomics, PTEN-related disorders, neurodevelopmental conditions, and molecular mechanisms of growth regulation. The research demonstrates interdisciplinary collaboration across genetics, neurology, and pediatrics with emphasis on translational applications. Cell Press 2021 Faces of Cell Pediatric Department Outstanding Research Award David W. Smith Pediatric Trainee Research Award Dr. Martinez-Agosto serves as Principal or Co-Principal Investigator on multiple NIH-funded research projects including studies on PTEN-associated autism, undiagnosed disorders, and Drosophila hematopoietic stem cell niches. His laboratory has trained numerous researchers in the field of medical genetics and developmental biology. His research is conducted through the Martinez Lab, which maintains active collaborations with multiple research groups at UCLA and other institutions, focusing on translational approaches to understanding genetic growth disorders.
Sahand Hormoz is an Assistant Professor at Harvard Medical School and a faculty member in the Department of Data Science at Dana-Farber Cancer Institute. His research focuses on controlling biological systems to understand cell state transitions and develop technologies for single-cell analysis, synthetic biology, and organoid modeling. PhD in Applied Physics from Harvard University (advised by Michael Brenner) Postdoctoral work at Kavli Institute for Theoretical Physics (UCSB) and Elowitz Lab at Caltech Research Interests His lab combines high-throughput single-cell measurements with differential geometry and machine learning to analyze complex biological data. They engineer cells for lineage tracing, develop organoid systems, and aim to automate biological modeling to overcome human cognitive limitations in understanding life systems. Publication Trends Key areas in his recent work include: Computational methods for single-cell and lineage analysis Cancer evolution in myeloproliferative neoplasms Synthetic biology tools for DNA-based cellular memory Integration of machine learning with biological dynamics Applications in stem cell biology and microbial systems Development of microfluidic platforms Labs & Teams Hormoz Lab at Harvard Medical School collaborates with Dana-Farber's Data Science Department to advance quantitative biology approaches.
Aaron P. Rapoport serves as the Gary Jobson Professor of Medical Oncology and Professor in the Department of Medicine at the University of Maryland School of Medicine. He holds dual leadership roles as Associate Chief of the Hematology/Oncology Division and Director of the Blood and Marrow Transplant Program at the UM Marlene and Stewart Greenebaum Comprehensive Cancer Center. His educational background includes a B.S. from Massachusetts Institute of Technology (1982) and M.D. from Harvard Medical School (1986), followed by postgraduate fellowships at University of Rochester/Strong Memorial Hospital (1989, 1993). Dr. Rapoport's research pioneers adoptive T-cell therapies for hematologic malignancies, with groundbreaking work in: Costimulated autologous T-cell infusions post-transplant MAGE-A3/Poly-ICLC vaccine combinations for myeloma High-affinity TCR gene-modified T cells Immune reconstitution strategies after stem cell transplantation His publication record (2005-2015) reveals an evolutionary trajectory from foundational immune recovery studies to advanced engineered cellular therapies, consistently targeting multiple myeloma through integrated vaccine and T-cell approaches. As Principal Investigator, he has secured major funding including: NHLBI R01-CA166961 (2012-2015) for gene-modified T-cell therapy Multiple Myeloma Research Foundation Senior Award (2013-2015) NHLBI R21 (2009-2010) for hTERT-based immunotherapy He directs the Blood and Marrow Transplant Program's translational research team, which has conducted over 6 clinical trials involving 150+ patients to develop novel cellular immunotherapies for hematopoietic cancers.
David Wiest is a Professor and the Scientific Director of the Research Institute at Fox Chase Cancer Center, affiliated with the Center for Immunology and the Nuclear Dynamics and Cancer (NDC) program. He leads a dynamic research laboratory focused on understanding the molecular mechanisms of T lymphocyte development, transformation, and immunodeficiency, with significant implications for cancer therapy. Dr. Wiest earned his PhD in Immunology from Duke University in 1991 and completed postdoctoral training in Developmental Immunology at the National Institutes of Health (NIH), finishing in 1995. His career has been dedicated to advancing knowledge in immunology and cancer biology through innovative research. His research interests center on the specification of αβ and γδ T cell lineages, the regulatory functions of ribosomal proteins like Rpl22 in hematopoiesis and leukemogenesis, the use of zebrafish models to identify disease-causing genes in immunodeficient humans, and the role of ERK2 substrate binding domains in cancer. His lab employs genome-wide approaches to uncover fundamental insights into immune cell development and applies this knowledge to improve cancer treatments. The lab's work spans from basic molecular mechanisms to translational applications, including developing anti-cancer immune effectors and novel therapeutic strategies for myeloproliferative disorders. His recent publications (2021–2025) reflect a strong focus on immune cell development, cancer signaling pathways (especially Ras/MAPK and STING), ribosomal protein functions, and the genetic basis of immunodeficiencies. Key themes include the role of transcription factors (TCF1, E proteins, Egr2) in cell fate decisions, metabolic regulation in leukemia, and the use of zebrafish for disease modeling and xenotransplantation studies. Dr. Wiest has been recognized with numerous scientific awards, including: American Cancer Society Southeastern Pennsylvania Research Award Norman F. Conant Award for Excellence in Research Election to the Henry Kunkel Society Cancer Research Institute Fellow NCI Board of Scientific Counselors Senior Research Excellence Award Bucks County Board of Associates Key to the Chapter Award Inspired Leadership Award He actively mentors students and postdoctoral fellows, including graduate student Billy Truong from Temple University, and collaborates with national and international researchers. His lab is a hub of scientific inquiry, with ongoing projects that integrate genetics, molecular biology, and immunology to address critical questions in cancer and immune disorders. The Wiest lab investigates how ribosomal proteins like Rpl22 and its paralog Rpl22-Like1 regulate hematopoietic stem cell potential and transformation, and how ERK2 domains can be targeted therapeutically in cancers with Ras/MAPK activation. The lab also uses zebrafish models to screen for human disease-causing mutations and study tumor xenotransplantation, contributing to both basic science and clinical applications.
Raymond Hohl, MD, PhD is the Director of the Penn State Cancer Institute and holds the Rice Family Foundation Professorship in the Penn State Cancer Institute within the Department of Medicine at Penn State College of Medicine. He serves as a Professor in the Department of Molecular and Precision Medicine and is a member of multiple research centers including the Division of Hematology and Oncology, the Advisory Committee of the Neuroscience Institute, the One Health Microbiome Center, and the Cancer Institute's Next-Generation Therapies program. Penn State Cancer Institute - Director Department of Medicine - Rice Family Foundation Professor Department of Molecular and Precision Medicine - Professor Division of Hematology and Oncology - Member Neuroscience Institute - Advisory Committee Member One Health Microbiome Center - Member Dr. Hohl is an internationally recognized expert in isoprenoid metabolism with extensive experience as a clinical and translational researcher. His primary research interests focus on human brain tumors, the isoprenoid pathway as it applies to human health and disease (specifically related to cancers), and prostate cancers. His work has significant implications for the UN Sustainable Development Goals, particularly those related to good health and well-being. Analysis of Dr. Hohl's recent publications reveals a strong focus on hematological malignancies and stem cell transplantation. His research spans multiple myeloma treatment optimization, GVHD prophylaxis strategies, infection prevention in transplant patients, and genetic factors affecting transplant outcomes. The work demonstrates a consistent translational approach connecting basic science discoveries to clinical applications. Carver Clinician, Scientist Award (1991) Clinical Pharmacology Faculty Development Award, Pharma Foundation (1992) Laureate Award, American College of Physicians (2001) Outstanding Research Award in Clinical Pharmacology, Central Society for Clinical Research (1995) Outstanding Research Award, GCRC Program Directors' Association (1996) Paul E. Carson, Pharmacology Award (1988) Young Investigator Award, American Society of Clinical Oncology (1992) Dr. Hohl has secured substantial research funding throughout his career, including the Cancer Center Support Grant (2000-2026) as Co-PI, Targeting the chondrosarcoma extracellular matrix for drug delivery (2014-2016) as PI, and multiple Career Development Programs funded by the National Cancer Institute. His research fingerprint reveals expertise in geranylgeranyl pyrophosphate, isoprenoids, bisphosphonates, and lovastatin pathways as they relate to malignant neoplasms. He leads the Cancer Institute's Next-Generation Therapies program and collaborates extensively with the One Health Microbiome Center and Neuroscience Institute.
Bri Jackson is a Lecturer in the Department of Foreign Language at Virginia Commonwealth University. While his formal academic role is in language education, his research focuses on advanced computational methods in pathology, including machine learning applications for cancer diagnosis, virtual immunohistochemistry, and digital pathology tools. His work spans histopathological analysis, immuno-oncology, and biomedical imaging. Jackson's research has led to the development of innovative algorithms for virtual diagnostic companion tools, foundation models for whole slide image analysis, and benchmarks for cervical cytology classification. His publications emphasize precision oncology, including biomarker multiplexing, molecular response prediction, and AI-driven histopathological interpretation. Key areas include non-small cell lung cancer, esophageal adenocarcinoma, and splenic involvement in pancreatic cancer prognosis. He has also explored educational challenges in pathology residency programs during the pandemic, viral epidemiology, and rare congenital disorders involving multiple organ systems. Jackson's work bridges computational biology with clinical diagnostics, though no scientific awards or student advisement details are mentioned in the available data.
Christopher A. Tormey, MD is a Professor of Laboratory Medicine at Yale University School of Medicine, where he serves as Director of the Transfusion Medicine Service and Director of the Transfusion Medicine Fellowship program. Board certified in Clinical Pathology and Blood Banking/Transfusion Medicine, Dr. Tormey provides clinical services at Yale-New Haven Hospital and VA Connecticut Healthcare System, specializing in transfusion medicine, laboratory hematology, and coagulation. Dr. Tormey's educational background includes a BA in Chemistry from the University of Chicago (2000), an MD from New York Medical College (2004), residency at Yale University School of Medicine (2007), and a Clinical Fellowship in Transfusion Medicine at Yale (2008). His research focuses on critical areas in transfusion medicine including alloimmunization to non-ABO antigens, platelet storage lesions, and optimization of hemostasis assays. Dr. Tormey has made significant contributions to understanding blood group incompatibility, coagulation testing, and platelet function disorders, with numerous publications addressing clinical challenges in transfusion practice. Analysis of Dr. Tormey's recent publications reveals a strong focus on transfusion safety, immunohematology, and clinical management of hematologic disorders. His work spans technical aspects of blood banking, clinical applications in pregnancy and sickle cell disease, and innovative approaches to therapeutic apheresis and stem cell transplantation. Dr. Tormey has received several prestigious awards including: AABB President's Award (2023) ASCP Mastership (2021) Yale School of Medicine Resident Teaching Award (2019) Ellis Benson Award (2015) 40 Under 40 Awardee (2014) As Director of the Transfusion Medicine Fellowship program, Dr. Tormey mentors future specialists in the field. His collaborative research involves extensive work with colleagues at Yale and other institutions, focusing on improving transfusion practices, understanding alloimmunization mechanisms, and optimizing patient care in hematologic conditions. Dr. Tormey is actively involved with the Apheresis/Transfusion Service and Blood Bank at Yale, contributing to clinical service delivery, research initiatives, and educational programs within the Department of Laboratory Medicine.
University of California, Los AngelesUnited States
Dr. Yvonne Yu-Hsuan Chen is a Professor at the University of California, Los Angeles (UCLA) School of Medicine, Department of Microbiology, Immunology, and Molecular Genetics. She earned her B.S. in Chemical Engineering from Stanford and a Ph.D. from Caltech, followed by postdoctoral training at Harvard Medical School and Seattle Children’s Research Institute. At UCLA since 2013, she co-directs the Tumor Immunology and Immunotherapy Program at the Jonsson Comprehensive Cancer Center and is a Parker Institute member. Education: Stanford (BS), Caltech (PhD), Harvard Medical School (Postdoc) Key research areas: Synthetic Biology, CAR-T cell engineering, tumor immunology, gene therapy Dr. Chen pioneers next-generation CAR-T therapies, focusing on overcoming tumor microenvironment challenges like hypoxia, antigen escape, and immune suppression. Her work integrates synthetic biology to reprogram T cells for enhanced specificity and metabolic compatibility with tumors. Recent studies highlight bispecific CARs, transgene silencing solutions, and metabolic reprogramming without antigen stimulation. Her publications span top journals like Nature Metabolism , Cell , and Cancer Discovery , emphasizing clinical translation. Collaborations include institutions like UCSF, Caltech, and Yale. Her lab trains future scientists, with alumni now at companies like Kite Pharma and institutions like Yale. Scientific awards: NIH Early Independence, ACGT Young Investigator, NSF CAREER Dr. Chen’s team includes PhD students and postdocs working on CAR-T trafficking, cytokine regulation, and tumor targeting. She leads clinical trials and translational research, aiming to improve CAR-T safety and efficacy for both hematologic and solid tumors.
Stuart Seropian, MD is a Professor of Internal Medicine (Hematology) at Yale School of Medicine and holds multiple leadership roles including Interim Director of the Stem Cell Transplant Program, Co-Director of CAR T-Cell Therapy, and Chairman of the Car-T Cell Joint Steering Committee at Yale-New Haven Hospital. He specializes in blood cancers such as leukemia, lymphoma, and multiple myeloma, with a focus on improving transplantation outcomes and novel anti-cancer therapies. Dr. Seropian completed his medical degree at George Washington University and residency/fellowship training at Yale-New Haven Hospital. Education: BS, Tufts University (1984) MD, George Washington University School of Medicine (1991) Residency and Fellowship, Yale-New Haven Hospital/Yale University School of Medicine (1996) Research Interests: Dr. Seropian's work centers on advancing hematologic malignancy treatments, including: Optimizing allogeneic stem cell transplantation protocols Developing targeted therapies like CAR T-cell and radioimmunotherapy Managing graft-versus-host disease Evaluating cost-effectiveness of novel therapies Improving outcomes in relapsed/refractory AML and lymphomas Clinical Trials: Leads/co-investigates studies in: CAR T-cell therapy for B-cell lymphomas Radioimmunotherapy (e.g., 131I-Apamistamab) for AML Combination therapies for multiple myeloma Phase III trials for targeted conditioning regimens Awards: Yale Cancer Center Clinical Excellence Award (2016) David S. Fischer Teaching Award (2014) Alpha Omega Alpha Honor Society (1991) Labs/Teams: Active in Yale’s Hematologic Malignancies Program, Cellular Therapies Program, and Stem Cell Transplantation team. Collaborates with industry partners on translational research.
